{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:26:28Z","timestamp":1794137188185,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF21OC0071977"],"award-info":[{"award-number":["NNF21OC0071977"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["1030-00168B"],"award-info":[{"award-number":["1030-00168B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008208","name":"Overl\u00e6ge Johan Boserup og Lise Boserups Legat","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008208","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Library, Copenhagen University Library","id":[{"id":"https:\/\/ror.org\/035b05819","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>Elevated remnant cholesterol is observationally and causally associated with increased risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. This association is not well studied in individuals with diabetes, who are often included in clinical trials of remnant cholesterol-lowering therapy. We tested the hypothesis that elevated remnant cholesterol is associated with increased risk of ASCVD in individuals with diabetes. We also explored the fraction of excess risk conferred by diabetes which can be explained by elevated remnant cholesterol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 4569 white Danish individuals with diabetes (58% statin users) nested within the Copenhagen General Population Study (2003\u20132015). The ASCVDs peripheral artery disease, myocardial infarction and ischaemic stroke were extracted from national Danish health registries without losses to follow-up. Remnant cholesterol was calculated from a standard lipid profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During up to 15 years of follow-up, 236 individuals were diagnosed with peripheral artery disease, 234 with myocardial infarction, 226 with ischaemic stroke and 498 with any ASCVD. Multivariable adjusted HR (95% CI) per doubling of remnant cholesterol was 1.6 (1.1, 2.3;\n                      <jats:italic>p<\/jats:italic>\n                      =0.01) for peripheral artery disease, 1.8 (1.2, 2.5;\n                      <jats:italic>p<\/jats:italic>\n                      =0.002) for myocardial infarction, 1.5 (1.0, 2.1;\n                      <jats:italic>p<\/jats:italic>\n                      =0.04) for ischaemic stroke, and 1.6 (1.2, 2.0;\n                      <jats:italic>p<\/jats:italic>\n                      =0.0003) for any ASCVD. Excess risk conferred by diabetes was 2.5-fold for peripheral artery disease, 1.6-fold for myocardial infarction, 1.4-fold for ischaemic stroke and 1.6-fold for any ASCVD. Excess risk explained by elevated remnant cholesterol and low-grade inflammation was 14% and 8% for peripheral artery disease, 26% and 16% for myocardial infarction, 34% and 34% for ischaemic stroke, and 24% and 18% for any ASCVD, respectively. LDL-cholesterol did not explain excess risk, as it was not higher in individuals with diabetes. We also explored the fraction of excess risk conferred by diabetes which can be explained by elevated remnant cholesterol.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>Elevated remnant cholesterol was associated with increased risk of ASCVD in individuals with diabetes. Remnant cholesterol and low-grade inflammation explained substantial excess risk of ASCVD conferred by diabetes. Whether remnant cholesterol should be used as a treatment target remains to be determined in randomised controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-023-06016-0","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:02:06Z","timestamp":1696032126000},"page":"2238-2249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1913-7472","authenticated-orcid":false,"given":"Benjamin N.","family":"Wadstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-4859","authenticated-orcid":false,"given":"Kasper M.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-8342","authenticated-orcid":false,"given":"Anders B.","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"6016_CR1","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"6016_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG (2016) Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 118(4):547\u201363. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306249","journal-title":"Circ Res"},{"issue":"9943","key":"6016_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/s0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626\u2013635. https:\/\/doi.org\/10.1016\/s0140-6736(14)61177-6","journal-title":"Lancet"},{"issue":"24","key":"6016_CR4","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","volume":"34","author":"AB Jorgensen","year":"2013","unstructured":"Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A (2013) Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 34(24):1826\u201333. https:\/\/doi.org\/10.1093\/eurheartj\/ehs431","journal-title":"Eur Heart J"},{"issue":"4","key":"6016_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/ana.25432","volume":"85","author":"A Varbo","year":"2019","unstructured":"Varbo A, Nordestgaard BG (2019) Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol 85(4):550\u2013559. https:\/\/doi.org\/10.1002\/ana.25432","journal-title":"Ann Neurol"},{"key":"6016_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab705","author":"BN Wadstrom","year":"2021","unstructured":"Wadstrom BN, Wulff AB, Pedersen KM, Jensen GB, Nordestgaard BG (2021) Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab705","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"6016_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.13646","volume":"21","author":"S Dash","year":"2019","unstructured":"Dash S, Leiter LA (2019) Residual cardiovascular risk among people with diabetes. Diabetes Obes Metab 21(Suppl 1):28\u201338. https:\/\/doi.org\/10.1111\/dom.13646","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6016_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dbi19-0007","volume":"69","author":"A Chait","year":"2020","unstructured":"Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE (2020) Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes 69(4):508\u2013516. https:\/\/doi.org\/10.2337\/dbi19-0007","journal-title":"Diabetes"},{"issue":"3","key":"6016_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/jcem.86.3.7304","volume":"86","author":"IJ Goldberg","year":"2001","unstructured":"Goldberg IJ (2001) Clinical review 124: diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 86(3):965\u201371. https:\/\/doi.org\/10.1210\/jcem.86.3.7304","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6016_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2213-8587(17)30362-5","volume":"6","author":"NJ Thomas","year":"2018","unstructured":"Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT (2018) Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 6(2):122\u2013129. https:\/\/doi.org\/10.1016\/S2213-8587(17)30362-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6016_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499\u2013502. https:\/\/doi.org\/10.1093\/clinchem\/18.6.499","journal-title":"Clin Chem"},{"issue":"1","key":"6016_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen P, Kangas AJ, Wurtz P, Suna T, Ala-Korpela M (2015) Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet 8(1):192\u2013206. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000216","journal-title":"Circ Cardiovasc Genet"},{"issue":"4","key":"6016_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1161\/CIRCRESAHA.116.304846","volume":"116","author":"A Varbo","year":"2015","unstructured":"Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A, Nordestgaard BG (2015) Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res 116(4):665\u201373. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.304846","journal-title":"Circ Res"},{"issue":"5","key":"6016_CR14","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/EDE.0000000000001378","volume":"32","author":"B Shi","year":"2021","unstructured":"Shi B, Choirat C, Coull BA, VanderWeele TJ, Valeri L (2021) CMAverse: a suite of functions for reproducible causal mediation analyses. Epidemiology 32(5):e20\u2013e22. https:\/\/doi.org\/10.1097\/EDE.0000000000001378","journal-title":"Epidemiology"},{"key":"6016_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab551","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ et al (2021) Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"6016_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/BF00145358","volume":"8","author":"BG Nordestgaard","year":"1992","unstructured":"Nordestgaard BG, Tybjaerg-Hansen A (1992) IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol 8(Suppl 1):92\u20138. https:\/\/doi.org\/10.1007\/BF00145358","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"6016_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco JB, Bartelink MEL et al (2018) 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 39(9):763\u2013816. https:\/\/doi.org\/10.1093\/eurheartj\/ehx095","journal-title":"Eur Heart J"},{"issue":"11","key":"6016_CR18","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1161\/hs1101.098524","volume":"32","author":"AJ Grau","year":"2001","unstructured":"Grau AJ, Weimar C, Buggle F et al (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32(11):2559\u201366. https:\/\/doi.org\/10.1161\/hs1101.098524","journal-title":"Stroke"},{"issue":"34","key":"6016_CR19","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","volume":"36","author":"E Ferrannini","year":"2015","unstructured":"Ferrannini E, DeFronzo RA (2015) Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36(34):2288\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehv239","journal-title":"Eur Heart J"},{"issue":"13","key":"6016_CR20","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.jacc.2017.08.006","volume":"70","author":"BG Nordestgaard","year":"2017","unstructured":"Nordestgaard BG (2017) A test in context: lipid profile, fasting versus nonfasting. J Am Coll Cardiol 70(13):1637\u20131646. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.006","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6016_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12944-017-0568-5","volume":"16","author":"CB Dias","year":"2017","unstructured":"Dias CB, Moughan PJ, Wood LG, Singh H, Garg ML (2017) Postprandial lipemia: factoring in lipemic response for ranking foods for their healthiness. Lipids Health Dis 16(1):178. https:\/\/doi.org\/10.1186\/s12944-017-0568-5","journal-title":"Lipids Health Dis"},{"issue":"6","key":"6016_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","volume":"46","author":"MR Taskinen","year":"2003","unstructured":"Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46(6):733\u201349. https:\/\/doi.org\/10.1007\/s00125-003-1111-y","journal-title":"Diabetologia"},{"issue":"2","key":"6016_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jacc.2018.04.050","volume":"72","author":"A Saeed","year":"2018","unstructured":"Saeed A, Feofanova EV, Yu B et al (2018) Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease. J Am Coll Cardiol 72(2):156\u2013169. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.050","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"6016_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jacc.2022.10.019","volume":"81","author":"M Balling","year":"2023","unstructured":"Balling M, Afzal S, Davey Smith G et al (2023) Elevated LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 81(2):136\u2013152. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6016_CR25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2337\/diacare.25.6.989","volume":"25","author":"EJ Schaefer","year":"2002","unstructured":"Schaefer EJ, McNamara JR, Shah PK et al (2002) Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham offspring study. Diabetes Care 25(6):989\u2013994. https:\/\/doi.org\/10.2337\/diacare.25.6.989","journal-title":"Diabetes Care"},{"key":"6016_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD, Paynter NP, Everett BM et al (2018) Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 206:80\u201393. https:\/\/doi.org\/10.1016\/j.ahj.2018.09.011","journal-title":"Am Heart J"},{"issue":"12","key":"6016_CR27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG (2013) Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 128(12):1298\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003008","journal-title":"Circulation"},{"issue":"2","key":"6016_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1373\/clinchem.2018.294926","volume":"65","author":"SEJ Hansen","year":"2019","unstructured":"Hansen SEJ, Madsen CM, Varbo A, Nordestgaard BG (2019) Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population. Clin Chem 65(2):321\u2013332. https:\/\/doi.org\/10.1373\/clinchem.2018.294926","journal-title":"Clin Chem"},{"issue":"25","key":"6016_CR29","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"issue":"12","key":"6016_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD et al (2017) Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 5(12):941\u2013950. https:\/\/doi.org\/10.1016\/S2213-8587(17)30313-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6016_CR31","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M et al (2019) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 7(8):618\u2013628. https:\/\/doi.org\/10.1016\/S2213-8587(19)30158-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"6016_CR32","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","volume":"75","author":"EK Duran","year":"2020","unstructured":"Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD (2020) Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease. J Am Coll Cardiol 75(17):2122\u20132135. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.059","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"6016_CR33","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","volume":"138","author":"AW Aday","year":"2018","unstructured":"Aday AW, Lawler PR, Cook NR, Ridker PM, Mora S, Pradhan AD (2018) Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence. Circulation 138(21):2330\u20132341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035432","journal-title":"Circulation"},{"key":"6016_CR34","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab533","author":"D Yu","year":"2021","unstructured":"Yu D, Wang Z, Zhang X et al (2021) Remnant cholesterol and cardiovascular mortality in patients with type 2 diabetes and incident diabetic nephropathy. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgab533","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6016_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12933-020-01076-7","volume":"19","author":"YX Cao","year":"2020","unstructured":"Cao YX, Zhang HW, Jin JL et al (2020) The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. Cardiovasc Diabetol 19(1):104. https:\/\/doi.org\/10.1186\/s12933-020-01076-7","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"6016_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12933-022-01667-6","volume":"21","author":"JH Huh","year":"2022","unstructured":"Huh JH, Han KD, Cho YK et al (2022) Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study. Cardiovasc Diabetol 21(1):228. https:\/\/doi.org\/10.1186\/s12933-022-01667-6","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"6016_CR37","doi-asserted-by":"publisher","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","volume":"6","author":"J Sundboll","year":"2016","unstructured":"Sundboll J, Adelborg K, Munch T et al (2016) Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 6(11):e012832. https:\/\/doi.org\/10.1136\/bmjopen-2016-012832","journal-title":"BMJ Open"},{"issue":"47","key":"6016_CR38","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","volume":"42","author":"A Varbo","year":"2021","unstructured":"Varbo A, Nordestgaard BG (2021) Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction. Eur Heart J 42(47):4833\u20134843. https:\/\/doi.org\/10.1093\/eurheartj\/ehab293","journal-title":"Eur Heart J"},{"issue":"5","key":"6016_CR39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ejvs.2016.12.031","volume":"53","author":"AN Lasota","year":"2017","unstructured":"Lasota AN, Overvad K, Eriksen HH, Tjonneland A, Schmidt EB, Gronholdt MM (2017) Validity of peripheral arterial disease diagnoses in the Danish National Patient Registry. Eur J Vasc Endovasc Surg 53(5):679\u2013685. https:\/\/doi.org\/10.1016\/j.ejvs.2016.12.031","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"21","key":"6016_CR40","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC et al (2022) Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 387(21):1923\u20131934. https:\/\/doi.org\/10.1056\/NEJMoa2210645","journal-title":"N Engl J Med"},{"issue":"5","key":"6016_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","volume":"15","author":"BG Nordestgaard","year":"2018","unstructured":"Nordestgaard BG, Nicholls SJ, Langsted A, Ray KK, Tybjaerg-Hansen A (2018) Advances in lipid-lowering therapy through gene-silencing technologies. Nat Rev Cardiol 15(5):261\u2013272. https:\/\/doi.org\/10.1038\/nrcardio.2018.3","journal-title":"Nat Rev Cardiol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06016-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-023-06016-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06016-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T19:03:07Z","timestamp":1699297387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-023-06016-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6016"],"URL":"https:\/\/doi.org\/10.1007\/s00125-023-06016-0","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We thank the staff and participants from the Copenhagen General Population Study for their valuable contributions. Some of the data were presented as an abstract at the European Atherosclerosis Society meeting in 2023.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The data cannot be shared due to regulations by the Danish Data Protection Agency. However, additional analyses can be performed upon reasonable request to the corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"We thank the Independent Research Fund Denmark (grant 1030-00168B), Novo Nordisk Foundation (grant NNF21OC0071977), Johan and Lise Boserup Fund, Aase and Ejnar Danielsen Fund and Herlev and Gentofte Hospital for providing funding. The funders had no role in the design of the study or collection, analysis, interpretation of data or in writing the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BGN reports consultancies and talks sponsored by AstraZeneca, Sanofi, Regeneron, Akcea, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Abbott and Silence Therapeutics. There are no competing interests for BNW, KMP or ABW.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"BNW planned and performed statistical analyses and wrote first draft of the paper. KMP, ABW and BGN revised the paper for critical scientific content, as well provided substantial support in the statistical analysis, and interpretation of the results. KMP independently verified key results. BGN defined the research topic jointly with the other authors. All authors read and approved the final manuscript. BNW and BGN are responsible for the integrity of the work as a whole.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}